Soft tissue sarcoma test kit SARCORNA™

oncologyfor precision medicineFFPE tissues

Targets 201 fusion genes in soft tissue and bone tumors Gene fusions are involved in up to 30% of sarcomas, arising from chromosomal rearrangements leading to translocations, insertions, inversions, or interstitial deletions. Conventional IHC, FISH and other methods however, cannot accurately locate gene fusions, as some exist in introns. Thus, DNA-level detection alone does not suffice as a comprehensive method of detection. Similarly, traditional RNA-Seq has insufficient sensitivity and low resolution while requiring higher quality samples, making it difficult to detect low-abundant fusion genes. Sarcorna™ uses targeted RNA sequencing technology to comprehensively detect gene fusions in sarcoma with increased sensitivity and dynamic range compared to whole transcriptome RNAseq. WHO IS IT FOR Recommended use: in conjunction with Sarcopact™ Patients with soft tissue and bone tumors requiring definitive diagnosis Patients with soft tissue and bone tumors seeking targeted therapy Patients with soft tissue and bone tumors who tested negative by conventional methods or by DNA alone SAMPLE TYPES Tumor tissue (FFPE block/slides, or frozen tissue) Fine needle biopsy